Replies to post #181568 on Biotech Values

[jq1234]

ACAD's Pimavanserin is a recent example. HGSI's Belimumab was one from a few years back.

[ghmm]

Maybe not the best example... InterMune's ASCEND trial was tweaked slightly based on one successful and one failed Phase 3. I give the company a lot of credit too, I was a bit skeptical the "tweak" would do much and was a bit worried it may back fire but it would appear that ASCEND results are superior to even the successful CAPACITY-2.